TOXICOLOGICAL SCIENCES, 179(1), 2021, 3–13 doi: 10.1093/toxsci/kfaa167 Advance Access Publication Date: 9 November 2020 Contemporary Review CONTEMPORARY REVIEW Can We Panelize Seizure? Ruth Roberts ,*,† Simon Authier,‡ R. Daniel Mellon,§ Michael Morton,* Downloaded from https://academic.oup.com/toxsci/article/179/1/3/5962077 by guest on 22 March 2021 Ikuro Suzuki,¶ Ronald B. Tjalkens,k Jean-Pierre Valentin,kk and Jennifer B. Pierson **,1 *ApconiX, Alderley Park, SK10 4TG, UK †University of Birmingham, B15 2SD, UK ‡Charles River Laboratories, Quebec, H7V 4B3, Canada §US Food and Drug Administration, Silver Spring, Maryland 20993 ¶Tohoku Institute of Technology, Sendai, 980-8577, Japan kDepartment of Environmental and Radiological Health Sciences, Colorado State University, Fort Collins, Colorado 80523 kkUCB Biopharma SRL, Early Solutions, Development Science, Investigative Toxicology, Chemin du Foriest, B-1420, Braine-l’Alleud, Belgium; and **Health and Environmental Sciences Institute, Washington, District of Columbia 20005 1To whom correspondence should be addressed at Health and Environmental Sciences Institute, MPH, 740 15th St, NW, Suite 600, Washington, DC 20005, USA. E-mail:
[email protected]. Disclaimer: This article reflects the views of the author and should not be construed to represent FDA’s views or policies. ABSTRACT Seizure liability remains a significant cause of attrition in drug discovery and development, leading to loss of competitiveness, delays, and increased costs. Current detection methods rely on observations made in in vivo studies intended to support clinical trials, such as tremors or other abnormal movements. These signs could be missed or misinterpreted; thus, definitive confirmation of drug-induced seizure requires a follow-up electroencephalogram study.